Business shareholder notification

Orbis Investment Management's Genmab Shareholding Fluctuations

Analysis based on 7 articles · First reported Mar 30, 2026 · Last updated Apr 14, 2026

Sentiment

Attention

Articles

Market Impact

Direct

Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard

Market Impact

The market impact is neutral as these are routine disclosures of changes in major shareholdings. While they provide transparency, the fluctuations in Orbis Investment Management's stake in Genmab are not significant enough to cause a major shift in market sentiment.

Biotechnology Investment Management

Event Summary

Genmab A/S, a biotechnology company, issued two major shareholder announcements regarding Orbis Investment Management Limited. The first announcement on April 1, 2026, stated that as of March 31, 2026, Orbis Investment Management Limited controlled 3,221,620 shares, amounting to 5.01% of Genmab's share capital and voting rights, thus crossing the 5% disclosure threshold under the Danish Capital Markets Act. The second announcement on April 14, 2026, indicated that as of April 13, 2026, Orbis Investment Management Limited's voting rights decreased to 3,114,318 shares, representing 4.85% of Genmab's share capital, falling below the 5% threshold.

Key Actions

80 Orbis Investment Management crossed major shareholder threshold Genmab

80 Orbis Investment Management decreased shareholding below threshold Genmab

70 Genmab announced major shareholder changes

Entities Involved

stock

Genmab

Genmab announced that Orbis Investment Management Limited's shareholding crossed a disclosure threshold, first exceeding 5% and then falling below it. This indicates changes in the ownership structure of Genmab.

Importance 100 Sentiment 0

priv

Orbis Investment Management

Orbis Investment Management Limited informed Genmab of changes in its voting rights, first exceeding 5.01% and then decreasing to 4.85% of Genmab's share capital. This reflects their active management of their investment in Genmab.

Importance 90 Sentiment 0

cnt

Denmark

Genmab is headquartered in Denmark, and the announcements are made under the Danish Capital Markets Act.

Importance 10 Sentiment 0

exch

Nasdaq

Genmab is listed on Nasdaq, indicating the exchange where its shares are traded.

Importance 10 Sentiment 0

Relationships

Orbis Investment Management related ↔ Genmab

Genmab related ↔ Denmark

NEWSDESK

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard